Vestal Point Capital LP raised its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 650.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 300,000 shares of the company's stock after purchasing an additional 260,000 shares during the quarter. Vestal Point Capital LP owned 1.07% of Establishment Labs worth $13,821,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. Quarry LP purchased a new position in shares of Establishment Labs in the fourth quarter worth $27,000. R Squared Ltd purchased a new position in shares of Establishment Labs in the fourth quarter worth $36,000. KLP Kapitalforvaltning AS purchased a new position in shares of Establishment Labs in the fourth quarter worth $161,000. Hood River Capital Management LLC lifted its holdings in shares of Establishment Labs by 236.4% in the fourth quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock worth $273,000 after buying an additional 4,160 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Establishment Labs by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock worth $378,000 after buying an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.
Establishment Labs Price Performance
ESTA traded down $0.23 during trading hours on Friday, hitting $36.62. The company's stock had a trading volume of 306,871 shares, compared to its average volume of 472,365. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $58.00. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -14.19 and a beta of 0.73. The business's 50-day moving average price is $34.33 and its 200-day moving average price is $37.95.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The business had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the previous year, the business posted ($0.58) earnings per share. The business's revenue was up 11.3% compared to the same quarter last year. Sell-side analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.
Analyst Ratings Changes
ESTA has been the topic of several research analyst reports. Needham & Company LLC raised shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 target price on the stock in a report on Wednesday, May 14th. Stephens reissued an "overweight" rating and issued a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Wall Street Zen downgraded shares of Establishment Labs from a "hold" rating to a "sell" rating in a report on Thursday. Finally, BTIG Research initiated coverage on shares of Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.33.
View Our Latest Analysis on Establishment Labs
About Establishment Labs
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Further Reading
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
